Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Receivables (2020 - 2026)

Neuroone Medical Technologies filings provide 7 years of Change in Receivables readings, the most recent being -$235349.0 for Q1 2026.

  • On a quarterly basis, Change in Receivables rose 88.52% to -$235349.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.1 million, a 989.87% increase, with the full-year FY2025 number at $1.1 million, up 516.05% from a year prior.
  • Change in Receivables hit -$235349.0 in Q1 2026 for Neuroone Medical Technologies, down from $1.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $2.2 million in Q4 2024 to a low of -$2.1 million in Q1 2025.
  • Median Change in Receivables over the past 5 years was $12098.0 (2022), compared with a mean of $150118.1.
  • Biggest five-year swings in Change in Receivables: surged 892.25% in 2023 and later crashed 16849.45% in 2025.
  • Neuroone Medical Technologies' Change in Receivables stood at $62082.0 in 2022, then skyrocketed by 775.29% to $543399.0 in 2023, then soared by 303.44% to $2.2 million in 2024, then tumbled by 36.27% to $1.4 million in 2025, then plummeted by 116.85% to -$235349.0 in 2026.
  • The last three reported values for Change in Receivables were -$235349.0 (Q1 2026), $1.4 million (Q4 2025), and $1.3 million (Q3 2025) per Business Quant data.